Avaliação terapêutica de um nanocompósito híbrido à base de lipossomas e pectina para liberação sustentada de norfloxacina em camundongos (Mus musculus) infectados

Abstract

The evolution of cases of bacterial resistance to current antibiotic formulations, the growing number of cases of superbugs, and the demand for methods to improve the effectiveness of known drugs instigated this study. One way to enhance the effect, half-life and decrease the side effects of antibiotics is by using liposomes as carriers of drug molecules. This work evaluated the effectiveness of different doses and administrations of a nanohybrid formulation of liposomes, pectin and norfloxacin (PEC@LUVNOR) in C57/6 mice experimentally infected with Pseudomonas aeruginosa PAO1 (PA PAO1) as a preliminary model for future tests in pets. At first, a literature review was carried out to present the context of the study better. In the second chapter, the results of a scientific article were presented. A total of 86 rodents were infected by PA PAO 1 and treated with two therapeutic and subtherapeutic doses (20 and 5mg/Kg) and two dosing interval schedules, being 24 hours post-infection (pi) in a single dose or 24 and 72 hours pi of PEC@LUV/NOR. The commercial formulation of norfloxacin was used in parallel. The results showed high efficiency in smaller doses of the nanohybrid formulation compared to commercial formulations, and greater ease of drug administration due to the need for fewer repetitions for the desired drug effect. Thus, the PEC@LUV/NOR nanohybrid formulation is an alternative with great potential to replace traditional formulations.